Gene Vector Market Size And Share [2023-2032 Report]

Gene Vector Market - By Vector (Plasmid DNA, Adeno-Associated Viral, Retroviral), By Application (Gene Therapy, Vaccinology), By Disease (Oncology, Genetic, Infectious) By End-user (CDMO, CRO, Pharma & Biotech Companies), Global Forecast 2023-2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast calculation

1.4&nbsp;&nbsp;&nbsp; Data Sources

1.4.1&nbsp;&nbsp;&nbsp; Secondary

1.4.1.1&nbsp;&nbsp;&nbsp;Paid sources

1.4.1.2&nbsp;&nbsp;&nbsp;Public sources

1.4.2&nbsp;&nbsp;&nbsp; Primary

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Gene vector 360&ordm; synopsis, 2018 &ndash; 2032

2.2&nbsp;&nbsp;&nbsp; Business trends

2.3&nbsp;&nbsp;&nbsp; Vector type trends

2.4&nbsp;&nbsp;&nbsp; Application trends

2.5&nbsp;&nbsp;&nbsp; Disease trends

2.6&nbsp;&nbsp;&nbsp; End user trends

Chapter 3&nbsp;&nbsp;&nbsp;Gene Vector Market Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Rising prevalence of genetic disorders, cancer, and infectious diseases

3.2.1.2&nbsp;&nbsp;&nbsp;Development of more advanced gene editing technologies

3.2.1.3&nbsp;&nbsp;&nbsp;Increasing demand for personalized medicine

3.2.1.4&nbsp;&nbsp;&nbsp;Increase in R&amp;D investments for the development of gene therapy

3.2.1.5&nbsp;&nbsp;&nbsp;Ongoing research into viral vector-based gene therapies

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;High cost of gene therapies

3.2.2.2&nbsp;&nbsp;&nbsp;Challenges associated with regulatory approval of gene vectors development

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By vector type

3.3.2&nbsp;&nbsp;&nbsp; By application

3.3.3&nbsp;&nbsp;&nbsp; By disease

3.3.4&nbsp;&nbsp;&nbsp; By end user

3.4&nbsp;&nbsp;&nbsp; COVID- 19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Technological analysis

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6.1&nbsp;&nbsp;&nbsp; U.S.

3.6.2&nbsp;&nbsp;&nbsp; Europe

3.7&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Market share analysis , 2022

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Gene Vector Market Size and Forecast, By Vector Type (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by vector type

5.2&nbsp;&nbsp;&nbsp; Plasmid DNA

5.3&nbsp;&nbsp;&nbsp; Retroviral

5.4&nbsp;&nbsp;&nbsp; Lentiviral

5.5&nbsp;&nbsp;&nbsp; Adenoviral

5.6&nbsp;&nbsp;&nbsp; Adeno-associated viral

5.7&nbsp;&nbsp;&nbsp; Other vector types

Chapter 6&nbsp;&nbsp;&nbsp;Gene Vector Market Size and Forecast, By Application (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by application

6.2&nbsp;&nbsp;&nbsp; Gene therapy

6.3&nbsp;&nbsp;&nbsp; Vaccinology

6.4&nbsp;&nbsp;&nbsp; Other applications

Chapter 7&nbsp;&nbsp;&nbsp;Gene Vector Market Size and Forecast, By Disease (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by disease

7.2&nbsp;&nbsp;&nbsp; Oncology

7.3&nbsp;&nbsp;&nbsp; Genetic disorders

7.4&nbsp;&nbsp;&nbsp; Infectious diseases

7.5&nbsp;&nbsp;&nbsp; Other diseases

Chapter 8&nbsp;&nbsp;&nbsp;Gene Vector Market Size and Forecast, By End-user (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by end-user

8.2&nbsp;&nbsp;&nbsp; CDMOs

8.3&nbsp;&nbsp;&nbsp; Pharmaceutical and biotechnology companies

8.4&nbsp;&nbsp;&nbsp; Research institutes

8.5&nbsp;&nbsp;&nbsp; CROs

Chapter 9&nbsp;&nbsp;&nbsp;Gene Vector Market Size and Forecast, By Region (USD Million)

9.1&nbsp;&nbsp;&nbsp; Key trends, by region

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; Japan

9.4.2&nbsp;&nbsp;&nbsp; China

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia and New Zealand

9.4.5&nbsp;&nbsp;&nbsp; Rest of Asia pacific

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

9.6&nbsp;&nbsp;&nbsp; MEA

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; Lonza

10.2&nbsp;&nbsp;&nbsp; Merck KGaA

10.3&nbsp;&nbsp;&nbsp; Thermo Fisher Scientific Inc.

10.4&nbsp;&nbsp;&nbsp; Oxford Biomedica

10.5&nbsp;&nbsp;&nbsp; Cobra Biologics

10.6&nbsp;&nbsp;&nbsp; Novasep

10.7&nbsp;&nbsp;&nbsp; Spark Therapeutics

10.8&nbsp;&nbsp;&nbsp; Kaneka Eurogentec

10.9&nbsp;&nbsp;&nbsp; Finvector Vision Therapies

10.10&nbsp;&nbsp;&nbsp; Brammer Bio

10.11&nbsp;&nbsp;&nbsp; Cell and Gene Therapy Catapult

10.12&nbsp;&nbsp;&nbsp; FUJIFILM Diosynth Biotechnologies

10.13&nbsp;&nbsp;&nbsp; uniQure N.V.

&nbsp;&nbsp;&nbsp;

Gene Vector Market

Inquiry Before Buying